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Objective: The Osteoarthritis Research Society International initiated a number of working groups to
address a call from the US Food and Drug Administration (FDA) on updating draft guidance on conduct of
osteoarthritis (OA) clinical trials. The development of disease-modifying osteoarthritis drugs (DMOADs)
remains challenging. The Assessment of Structural Change (ASC) Working Group aimed to provide
a state-of-the-art critical update on imaging tools for OA clinical trials.
Methods: The Group focussed on the performance metrics of conventional radiographs (CR) and magnetic
resonance imaging (MRI), performing systematic literature reviews for these modalities. After acquiring
these reviews, summary and research recommendations were developed through a consensus process.
Results: For CR, there is some evidence for construct and predictive validity, with good evidence for
reliability and responsiveness of metric measurement of joint space width (JSW). Trials off at least 1 and
probably 2 years duration will be required. Although there is much less evidence for hip JSW, it may
provide greater responsiveness than knee JSW. For MRI cartilage morphometry in knee OA, there is some
evidence for construct and predictive validity, with good evidence for reliability and responsiveness. The
responsiveness of semi-quantitative MRI assessment of cartilage morphology, bone marrow lesions and
synovitis was also good in knee OA.
Conclusions: Radiographic JSW is still a recommended option for trials of structure modiﬁcation, with the
understanding that the construct represents a number of pathologies and trial duration may be long. MRI
is now recommended for clinical trials in terms of cartilage morphology assessment. It is important to
study all the joint tissues of the OA joint and the literature is growing on MRI quantiﬁcation (and its
responsiveness) of non-cartilage features. The research recommendations provided will focus
researchers on important issues such as determining how structural change within the relatively short
duration of a trial reﬂects long-term change in patient-centred outcomes.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.: P.G. Conaghan, Section of
eds LS7 4SA, UK. Tel: 44-113-
aghan).
s Research Society International. PIntroduction
Current status of guidance for assessing osteoarthritis (OA) disease
modiﬁcation
The development of disease-modifying osteoarthritis drugs
(DMOADs) is faced with many challenges. There remains an inad-
equate understanding of the primary endpoint for demonstrating
DMOAD efﬁcacy. The actual result of clinical OA symptomatic
progression, arthroplasty, is associated with multiple problems asublished by Elsevier Ltd. All rights reserved.
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surgery, in part related to socioeconomic disparities, different
healthcare environments and the relatively low incidence rate of
arthroplasties compared with the total OA burden1,2. Alternative
clinical endpoints for DMOAD clinical trials have therefore been
considered and the Food and Drug Administration (FDA) previously
provided regulatory draft guidelines for use in DMOAD develop-
ment3. The FDA Clinical Development Programs for Drugs, Devices
and Biological Products Intended for the Treatment of OA draft
guidelines deﬁned the current acceptable structural endpoint for
DMOAD clinical trials as a slowing in the loss of knee or hip joint
space narrowing (JSN) using conventional radiographs (CR);
depending on the structural change this would need to be
accompanied by symptom improvement. Similar recommenda-
tions were adopted by the European Medicines Agency (EMEA) in
Europe4 (also adopted by the Therapeutic Goods Administration
(TGA) in Australia) and remain in their recently revised Guideline5.
The current hierarchy of claims for structural outcome as
deﬁned by the FDA Clinical Development Programs for Drugs,
Devices and Biological Products Intended for the Treatment of OA
draft guidance is as follows:
1. Normalise the X-ray (reverse progression).
2. Improve the X-ray (halt progression).
3. Slow JSN by at least a pre-speciﬁed amount (slow the rate of
progression).
CR have traditionally been the method of choice in clinical trials
because of their relative feasibility. Until recently, it was widely
accepted that alteration in progression of JSN implies preservation of
hyaline cartilage and consequently clinical beneﬁt; measurement of
joint space width (JSW) by X-ray was determined as the most
appropriate structural endpoint measure6,7. However it was recog-
nized that the nature and magnitude of structural changes that are
likely to be clinically relevant remain uncertain. Whether parallel
clinical outcomes should be included in the claim depends on what
JSW outcome is achieved, but collection of these data (including
measurementofpain, apatient globalassessment, a self-administered
questionnaire and the time to the need for total joint replacement
surgery) was strongly recommended regardless of the anticipated
outcome since their assessment is critical for analysis of the overall
risks and beneﬁt of a product3. Since the concept of structural
improvement connotes an element of durability, trials to demonstrate
structure improvement were recommended to last at least 1 year3.
As well, owing to the rapid growth of magnetic resonance
imaging (MRI) studies in the last decade, there has been an
increased awareness that symptomatic OA represents a process
involving all the tissues in the OA joint, not just cartilage8,9. MRI has
evolved substantially over the last decade and its strengths include
its ability to visualise individual tissue pathologies, as well as the
interrelationship between tissue pathologies.
Limitations of JSN as an outcome
Although a product showing a slowing of JSNwould be expected
to also affect symptoms, it is possible that certain products may
affect structural progression without associated symptomatic
evidence10. It is also possible that slowing of structural progression
mayoccur at an earlier time-pointwith later reduction in symptoms
(acknowledged in the recent EMEAGuideline5). A claimof structural
improvement (i.e., slowing of JSN) might conceivably be dissociated
from other claims when the mechanism of action of the product,
and/or the size of the effect on slowing of JSN, are suggestive of
future clinical beneﬁts. If products are not anticipated to have
different effects on these parameters or show only smallimprovements in JSN without demonstrated effects in symptoms
they will not generally be considered for approval or for separate
claims. In other words, as long as an observed delay in JSN
progression is correlated to an improvement of clinical outcomes it
is considered as an appropriate primary endpoint and as a surrogate
endpoint for total joint replacement, the critical event characteristic
of medical treatment failure for OA. It is assumed that a delay in JSN
will consequently delay the need for total joint surgery, and can
hence be interpreted as a treatment success for DMOADs.
The use of JSN measured by CR as a structural endpoint is associ-
atedwith some concerns. Since disease progression is generally slow,
minimal and variablewithin andbetween subjects10,11, the use of JSW
as an endpoint measurement requires long-term treatment periods
(>1 year) and inclusions of large patient numbers. Moreover, the
inabilityof radiographs tovisualise cartilage leads to lackof sensitivity
to detect early and small changes in this tissue12. There is difﬁculty in
obtaininghighquality reproducible images of OA joints, despite state-
of-the-art standardisation of radiographic protocols to reduce the
variability related to joint repositioning13. MRI studies have demon-
strated that JSN represents a complex of hyaline cartilage loss,
meniscal extrusion and meniscal degeneration14. Although structure
is a critical component of OA assessment, the relationships between
structure and pain and/or function and between structure and future
outcomes (e.g., arthroplasty) are not well developed and the deﬁni-
tion of a clinically relevant change in JSN has not been established.
The use of JSWalonemay not be entirely relevant as an outcome
measure for DMOAD efﬁcacy since it fails to capture the multi-
tissue nature of OA9,15. As such, potential early beneﬁcial changes in
other components of the joint are missed by the use of JSN alone as
the structural endpoint. Moreover, the insensitivity of JSN to early
changes in cartilage and meniscus means that even “moderate” OA
knees (KellgreneLawrence 2) may already represent a stage of
the disease too molecularly and biochemically advanced for alter-
ation of disease course by pharmacological intervention. Previous
attempts at OA disease modiﬁcation using JSN as an endpoint have
provided important lessons about the design and conduct of such
trials, including issues on radiographic positioning, measurement
methods, and study “enrichment” for progressors in order to
ensure progression in the placebo group; this has been previously
well reviewed7,16. Despite the limitations as a measure for DMOAD
efﬁcacy, delay in JSN has been reported for a small number of
potential DMOADs to date7,16. However the lack of associated
symptomatic beneﬁt in these studies has prevented any of these
agents from being successfully registered.
Methods
In the last decade since the FDA produced its draft guidance for
industry, much evidence has been accumulated on the assessment
of structural change in OA. The Osteoarthritis Research Society
International (OARSI) FDA OA Assessment of Structural Change
(ASC) Working Group comprised a wide range of expertise
including clinical trialists, methodologists, academics, imaging
experts and pharmaceutical company representatives with rele-
vant trials experience; the Group was tasked with:
1. Examining a number of key issues about the performance
metrics (including predictive validity for relevant clinical
outcomes and responsiveness) of the commonest imaging tools
used to assess structural change in OA, focussing predomi-
nantly on CR and MRI, while brieﬂy examining the information
on other modalities especially the growing ﬁeld of ultrasound.
This was performed by conducting systematic literature
reviews for CR and MRI. The draft strategy for the literature
review was written in December 2008, sent to all members of
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a ﬁnal version of the protocol was approved in February 2009.
Details of the protocol and the search terms are published
separately17e20. The literature search was conducted using
articles published up to the time of the search in April 2009. For
examining the role of ultrasound, where it was acknowledged
there was a much smaller literature base, we used a recently
published systematic literature review on ultrasound in OA21.
2. Producing state-of-the-art recommendations in assessing OA
structural change for the purposes of optimising utilisation in
OA clinical trials, based on the ﬁndings of the systematic
literature reviews and via a consensus approach.
3. To also develop research recommendations again based on the
literature reviews and through a consensus process of the ASC
Working Group.
The following summary and derived recommendations
attempts to overview the large amount of literature reviewed
during this process. Much of the work summarised below is
detailed in the more detailed accompanying systematic reviews of
both radiography and MRI17e20; for this reason, individual refer-
ences supporting each statement are not provided in this summary.
Summary and recommendations
The underlying assumption of these recommendations is that
the manifestations of joint pain and disability currently associated
with OA are strongly related to the pathophysiology of OA seen in
joint structures. This postulate is to some extent supported by
epidemiological evidence of the association between radiographic
OA, joint pain and disability in the general population.
Much of the published evidence on imaging ASC relates to OA of
the knee, with much less evidence (especially for modern imaging
modalities) relating to OA of the hip and very limited information
available forhandOA. This summarymust thereforebeseenas largely
related to trials for OA of the knee and to a lesser extent, the hip.
Importantlymost of the therapeutic studies onOAhave included
symptomatic and radiographically moderate to severe OA, so there
is an absence of literature and deﬁnitions for “early” OA, especially
studies entering people before the currently recognized clinical
syndrome is apparent andwhen structural pathology is presumably
minimal. So the literature on the performance of existing imaging
modalities at this important stage of the OA process is sparse.
When mentioned, the term ‘therapies’ refers to drugs, devices
and biological products entered into the treatment of OA and
regulated by the FDA; this could also include interventions such as
weight loss.
Conventional radiography
 CR presents an image of the joint space of a diarthrodial joint,
the width of which represents the thickness of articular carti-
lage. In some joints, notably the knee, JSW also reﬂects the
presence, location and condition of other structures (e.g.,
meniscus), and JSW is a composite measure of the combined
thickness of those structures. This should be considered when
deﬁning a relevant knee trial outcome.
 Much is now known of the performance metrics of CR JSW in
the knee and to a lesser extent in the hip. There is some
evidence for construct and predictive validity, with good
evidence for reliability and responsiveness of metric
measurement of JSW. In terms of correlations with concurrent
symptoms, there is a weak association between progression in
JSN and progression of symptoms. There is little information on
how progression in JSN during the course of a study reﬂectspost-study (long-term) change in symptoms. JSN progression is
associated with increased rate of subsequent total joint
replacement, but these may not be truly independent events as
radiographic JSN is one of the features used to select people for
joint replacement surgery.
 In the knee, the use of ﬂuoroscopic positioning and semi-ﬂexed
views improve responsiveness, although it is acknowledged that
access to ﬂuoroscopic facilities is restricted. Studies will gener-
ally need to be at least 12 and more likely 24 months duration.
 It is possible and therefore advisable to ‘enrich’ a knee OA study
population to increase the rate of joint space loss, for example,
by including higher Kellgren Lawrence (KL) grade.
 Automated methods for assessing parameters of JSW offer
promise of improved precision and therefore improved
responsiveness.
 The natural history of hip OA appears different to that of knee
OA and although the literature concerning the hip is much less
extensive, there is some evidence for better responsiveness for
JSW measurement at the hip. Hip JSW as a construct does not
include a meniscus. There is little evidence on enriching
cohorts for purposes of increasing rate of JSN progression.
 We support the continued use of CR JSW as one option for
assessing structural OA change, taking all the previous points
into account when deciding on study endpoint.Research recommendations
To further understand the relationship between JSN and
symptoms, future studies should focus on the following areas:
 Cross-sectional studies in which the patients are their own
controls (such as one recently published22) to better evaluate
the potential correlation.
 Longitudinal studies evaluating the relationship between
changes in symptoms and changes in joint space.
 Predictive validity studies, i.e., does joint space predict subse-
quent pain and disability and subsequent joint replacement?
For example, does JSN between month 0 and month 12
correlates with joint replacement by month 60?
 Construct validity studies, i.e., correlation between JSN and
mean pain or function. For example, is JSW between month
0 and month 12 correlated with mean pain and function
evaluated every 6 months between month 0 and month 12, or
between month 12 and month 24?
For Knee OA:
 Studies of the relationship between symptoms and radio-
graphic joint space evaluated on semi-ﬂexed X-rays with
ﬂuoroscopy.
 Studies on predictors of joint loss evaluated on semi-ﬂexed
X-rays with ﬂuoroscopy and optimal serial tibial plateau
alignment.
 Studies on the effect of rate of joint space loss on treatment
effect.
For Hand OA:
 Studies comparing the metrological properties of hand OA
scoring systems.
MRI
 For assessing MRI cartilage morphometry in knee OA, there is
some evidence for construct and predictive validity, with good
evidence for reliability and responsiveness. Using MRI it is
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morphology over 12 months for knee OA and we recommend
the use ofMRI for assessing cartilagemorphology in trials of OA
structure modiﬁcation.
 It is possible to ‘enrich’ a knee OA study population with MRI
outcomes in order to increase the rate of cartilage loss, for
example, by including higher KL grade.
 In terms of correlations with concurrent symptoms, there is
a weak association between progression of cartilage loss and
increasing symptoms. There is little information on how
change in cartilage parameters during the course of a study
reﬂects post-study change in symptoms. There is some
predictive validity with progression of cartilage loss predicting
subsequent total joint replacement.
 More information is required on the performance metrics of
MRI semi-quantitative and compositionalmeasures of cartilage
morphology. There may be a role for semi-quantitative
assessments for assessing focal cartilage defects.
 Structure modiﬁcation should be considered in a broader
context than that of cartilage alone. Since MRI has the capacity
to image the other tissues, further work is needed on the
quantiﬁcation and predictive validity of non-cartilage MRI
pathologies. The performance metrics of non-cartilage MRI
features have not been extensively studied but there is
a rapidly emerging literature in this ﬁeld.Research recommendations
As well as the areas recommended above, including research
into ‘whole organ’ or multi-tissue assessment (currently via semi-
quantitative scores) and improving the quantiﬁcation of non-
cartilage pathologies, the MRI OA ﬁeld needs:
 Studies to deﬁne more responsive measures of structural
change.
 Studies that measure change at an earlier stage of diseasewhen
it may be more suitable for DMOAD intervention.
 Studies to improve predictive validity of current structural
measures for important clinical outcomes (e.g., total joint
replacement (TJR), virtual TJR).
 Studies to improve assessment precision of structural
measures more closely related to symptom change (e.g., bone
marrow lesions, synovitis).
Other imaging modalities
The potential for non-CR or MRI modalities to assess relevant
non-cartilage tissues should be considered. Ultrasound is currently
the other recent imagingmodality withmost information available,
and at this stage it appears it is most promising as a tool for eval-
uating OA synovitis. Ultrasound-detected pathologies have been
associated with current OA symptoms. Further work is required to
better understand the performance metrics of ultrasonographic
quantiﬁcation of pathology, with such work requiring improved
pathology deﬁnitions.
Conclusions
The amount of publications assessing OA structural change has
dramatically increased over recent years, related to the availability
of large cohort studies. Though we now understand CR JSW
represents a complex of pathologies, gaps still remain in our
understanding of both construct and predictive validity. The
growth of MRI as an OA imaging biomarker has evolved to a point
where it can be recommended for clinical trials in terms of cartilagemorphology assessment. Much still needs to be understood about
compositional cartilage measures and just as importantly, quanti-
ﬁcation of non-cartilage features. The literature reviews performed
by the ASC Working Group, together with attention to the research
recommendations listed here, should ensure that the current gaps
in our knowledge regarding the performance metrics and clinical
importance of existing tools will be ﬁlled.
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